Amid EpiPen shortage, a Canadian-based company has approval for an alternative

Lily Brennan holding EpiPen

Bausch Health, headquartered in Laval, Que., says it is “actively seeking” to bring its adrenaline autoinjector — which works in a similar way to the EpiPen — to the Canadian market.

Go to Source